Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 701–800 of 1,006
Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome
Chakraborty, S., Ganie, M. A., Masoodi, I., Jana, M., Shalimar, S., Gupta, N., & Sofi, N. Y. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_610_18 · Cited by 26
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
Raperport, C., Chronopoulou, E., & Homburg, R. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1889366 · Cited by 26
Cao, Q., Hu, Y., Fu, J., Huang, X., Wu, L., Zhang, J., & Huang, W. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15044 · Cited by 26
“these metabolic disorders, IR is most likely a cornerstone of the pathophysiology of PCOS.(5,6) Metformin is the first-line drug for PCOS.”
BackgroundInfluentialBovine models for human ovarian diseases
Roberts, J. F., & Huang, C. J. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.02.001 · Cited by 26
Maffazioli, G. D. N., Baracat, E. C., Soares, J. M., Carvalho, K. C., & Maciel, G. A. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275031 · Cited by 26
“This may be justified based on this miRNA role in angiogenesis, that culminate with the PI3K-AKT [45] signaling pathway, dysregulation, which is common in women with PCOS and insulin resistance [46].”
BackgroundEl-Eshmawy, M. M., Ibrahim, A. A. E. W., Bahriz, R., Shams-Eldin, N., & Mahsoub, N. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01240-y · Cited by 26
Panda, S. P., Kesharwani, A., Singh, G. D., Prasanth, D., Vatchavai, B. R., Kumari, P. V. K., Panda, S. K., & Mallick, S. P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102086 · Cited by 27
Polycystic ovary syndrome and risk of pre‐eclampsia: A national register‐based cohort study
Valdimarsdottir, R., Vanky, E., Elenis, E., Lindström, L., Junus, K., Jonsson, M., Poromaa, I. S., & Wikström, A. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17734 · Cited by 26
Glintborg, D., Ollila, M., Møller, J. K., Pesonen, P., Persson, S., Elenis, E., Rubin, K. H., Gissler, M., Andersen, M., Poromaa, I. S., et al. (2024) · Human Reproduction · doi:10.1093/humrep/deae124 · Cited by 26
Zhang, D., Cong, J., Huanhuan, S., Wu, Q., & Wu, X. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1203 · Cited by 26
Milutinović, D., Nikolić, M., Veličković, N., Djordjevic, A., Bursać, B., Nestorov, J., Teofilović, A., Antić, I., Macut, J., Zidane, A., et al. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-104531 · Cited by 21
Finnbogadóttir, S. K., Glintborg, D., Jensen, T. K., Kyhl, H. B., Nohr, E. A., & Andersen, M. (2017) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13200 · Cited by 26
“We found that 40% of women with PCOS were overweight before gestation, which was lower than observed in other studies (6, 24).”
BackgroundResultAdamska, A., Polak, A. M., Krentowska, A., Łebkowska, A., Hryniewicka, J., Leśniewska, M., & Kowalska, I. (2019) · Endocrine Connections · doi:10.1530/ec-19-0243 · Cited by 26
Hassani, F., Oryan, S., Eftekhari‐Yazdi, P., Bazrgar, M., Moini, A., Nasiri, N., & Ghaheri, A. (2019) · PubMed Central · doi:10.22074/ijfs.2019.5422 · Cited by 26
“According to some studies, insulin resistance is not a disease but it can develop numerous metabolic alterations (34, 35).”
BackgroundSerum Metabolomics in PCOS Women with Different Body Mass Index
Ożegowska, K., Plewa, S., Mantaj, U., Pawelczyk, L. A., & Matysiak, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132811 · Cited by 27
“In addition, PCOS impacts menstrual regularities, fertility, and dermatological complications and may induce metabolic disturbances, diabetes, and coronary heart disease [17,18].”
BackgroundOlszanecka‐Glinianowicz, M., Madej, P., Wdowczyk, M., Owczarek, A. J., & Chudek, J. T. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0539 · Cited by 26
Cheema, B. S., Vizza, L., & Swaraj, S. (2014) · Sports Medicine · doi:10.1007/s40279-014-0206-6 · Cited by 27
“Hyperandrogenemia, in turn, may also exacerbate insulin resistance and fat accumulation in the peripheral tissues (muscle and fat cells) [52, 55, 56], creating a self-perpetuating cycle of fat accumulation, insulin resistance and androgen excess.”
BackgroundGül, Ö. Ö., Cander, S., Gul, C. B., Açıkgöz, E., Sarandöl, E., & Ersoy, C. (2015) · European Cytokine Network · doi:10.1684/ecn.2015.0370 · Cited by 26
“olycystic ovary syndrome (PCOS) is a common, ultifaceted endocrinopathy associated with metabolic lterations such as insulin resistance, hyperinsulinemia, yslipidemia, and obesity, and thereby an increased risk f developing type 2 diabetes mellitus (T2DM) and cariovascular disease (CVD) [1-3].”
BackgroundDravecká, I., Figurová, J., Javorský, M., Petríková, J., VAĽKOVÁ, M., & Lazúrová, I. (2016) · Physiological Research · doi:10.33549/physiolres.933266 · Cited by 26
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Li, F., Qi, J.-J., Li, L., & Yan, T.-F. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.05.042 · Cited by 26
Guo, F., Huang, Y., Fernando, T., & Shi, Y. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00845-x · Cited by 25
“In response to stimulation by insulin, these vesicles are translocated to the cell surface to promote glucose uptake [78, 79].”
BackgroundZhao, J., Sui, X., Shi, Q., Su, D., & Lin, Z. (2022) · Medicine · doi:10.1097/md.0000000000030006 · Cited by 25
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 26
“glucose abnormalities and the cardiometabolic risk of PCOS, even though the mechanisms of insulin resistance in PCOS are not well defined.(37) Studies suggest that excess androgen causes conformational changes in the insulin receptor transduction, leading to under‐ regulation and disturbance of its sensing capabilitie…”
BackgroundUnlocking the Potential of Mesenchymal Stem Cells in Gynecology: Where Are We Now?
Ivkošić, I. E., Fureš, R., Ćosić, V., Mikelin, N., Bulić, L., Dobranić, D., Brlek, P., & Primorac, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13081253 · Cited by 25
Matsumoto, T., Alves-Lopes, R., Taguchi, K., Kobayashi, T., & Tostes, R. C. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.12.216 · Cited by 25
“Women with polycystic ovary syndrome, who present with hyperinsulinemia, insulin resistance, and hyperandrogenemia, appear to be at higher risk for T2DM and exhibit elevated ET-1 levels (Diamanti-Kandarakis and Dunaif, 2012; Imbar et al., 2012).”
BackgroundMoghetti, P., Carmina, E., Leo, V. D., Lanzone, A., Orio, F., Pasquali, R., & Toscano, V. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0274-y · Cited by 25
“Interestingly, insulin suppression by pharmacological intervention can decrease serum androgens in women with PCOS, but not in healthy women, suggesting that PCOS-specific abnormalities may be a prerequisite for the reproductive effects of insulin [15].”
BackgroundGupta, D., Khan, S., Islam, M., Malik, B. H., & Rutkofsky, I. H. (2020) · Cureus · doi:10.7759/cureus.8079 · Cited by 25
Liu, M., Zhu, H., Yin, L., Zhuang, J., Cao, T., & Wang, Y. (2020) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2020.03.006 · Cited by 25
Metabolic Disturbance in PCOS: Clinical and Molecular Effects on Skeletal Muscle Tissue
Dantas, W. S., Gualano, B., Rocha, M. P., Barcellos, C. R. G., Yance, V. D. R. V., & Marcondes, J. A. M. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/178364 · Cited by 26
“This wide range may be due to several factors, including the heterogeneity of the diagnostic criteria for PCOS employed in these studies [22], the genetic background among the assessed population [6], and the differences regarding the methods used for defining IR [22, 25, 26].”
BackgroundMethodInfluentialInsulin Increases Phosphorylation of Mitochondrial Proteins in Human Skeletal Musclein Vivo
Zhao, X., Bak, S. Y., Pedersen, A. J. T., Jensen, O. N., & Højlund, K. (2014) · Journal of Proteome Research · doi:10.1021/pr401163t · Cited by 25
The high responder: a review of pathophysiology and outcomes during IVF treatment
Mascarenhas, M., & Balen, A. H. (2017) · Human Fertility · doi:10.1080/14647273.2017.1293851 · Cited by 25
Yu, Y., Fang, L., Zhang, R., He, J., Xiong, Y., Guo, X., Du, Q., Huang, Y., & Sun, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-03803-9 · Cited by 25
Johnson, L. K., Holven, K. B., Nordstrand, N., Mellembakken, J. R., Tanbo, T., & Hjelmesæth, J. (2015) · Endocrine Connections · doi:10.1530/ec-15-0047 · Cited by 24
Oliveira, Í. M. D., Araújo, R. N., Branquinho, P. L., Neto, A. O. D. S., Lopes, C. T. D. O., & Bulla, L. L. (2024) · Journal of Social Issues and Health Sciences (JSIHS) · doi:10.5281/zenodo.13121543 · Cited by 24
Mu, J., Yu, P., & Li, Q. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.01.008 · Cited by 24
Wang, Y., Zeng, Z., Zhao, S., Tang, L., Yan, J., Li, N., Zou, L., Fan, X., Xu, C., Huang, J., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab056 · Cited by 24
Abdalla, M. A., Shah, N. Z., Deshmukh, H., Sahebkar, A., Östlundh, L., Al‐Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2021) · Clinical Endocrinology · doi:10.1111/cen.14623 · Cited by 24
“The majority of obese and lean women with PCOS have shown to have clinical evidence of acanthosis nigricans.(6) Moreover, hyperinsulinemia increases the risk of T2DM, and over 11% of overweight/obese women with PCOS develop diabetes.”
BackgroundAbdel–Mottaleb, Y., Ali, H. S., El-Kherbetawy, M. K., Elkazaz, A. Y., ElSayed, M. H., Elshormilisy, A. A., Eltrawy, A. H., Abed, S. Y., Alshahrani, A. M., Hashish, A. A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112639 · Cited by 24
Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS
Ryssdal, M., Vanky, E., Stokkeland, L. M. T., Jarmund, A. H., Steinkjer, B., Løvvik, T. S., Madssen, T. S., Iversen, A., & Giskeødegård, G. F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad145 · Cited by 24
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome
Livadas, S., Paparodis, R. D., Anagnostis, P. G., Gambineri, A., Bjekić-Macut, J., Petrović, T., Yıldız, B. O., Micić, D., Mastorakos, G. P., & Μacut, D. (2023) · Diagnostics · doi:10.3390/diagnostics13122067 · Cited by 24
Jiang, N.-X., Zhao, W., Shen, H., Du, D., & Li, X. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-023-01334-8 · Cited by 24
Lipid homeostasis is essential for oogenesis and embryogenesis in the silkworm, Bombyx mori
Fangying, Y., Xu, X., Hu, B., Zhang, Z., Chen, K., Yu, Y., Bai, H., & Tan, A. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05173-8 · Cited by 24
“Several human metabolic disorder diseases, such as lipodystro-phy and insulin resistance, are generally accompanied by impaired fecundity [5, 6].”
BackgroundBahreiny, S. S., Ahangarpour, A., Harooni, E., Amraei, M., Aghaei, M., & Fard, R. M. (2025) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v22i12.18061 · Cited by 24
Hyperandrogenism Decreases GRP78 Protein Level and Glucose Uptake in Human Endometrial Stromal Cells
Rosas, C., Oróstica, L., Poblete, C., Carvajal, R., Gabler, F., Romero, C., Lavandero, S., & Vega, M. (2016) · Reproductive Sciences · doi:10.1177/1933719115618283 · Cited by 25
“Polycystic ovary syndrome is an endocrine–metabolic disorder present in 5% to 10% of women in fertile age, characterized by a clinical and/or biochemical hyperandrogenism.(6) Also, a higher pregnancy failure risk with a 30% to 50% probability of miscarriage in women with PCOS, compared to normal population, has been r…”
BackgroundHao, M., Yuan, F., Jin, C., Zhou, Z., Cao, Q., Xu, L., Wang, G., Huang, H., Yang, D., Xie, M., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1234 · Cited by 24
Morrison, S. A., Goss, A. M., Azziz, R., Raju, D. A., & Gower, B. A. (2016) · Human Reproduction · doi:10.1093/humrep/dew279 · Cited by 24
“…et al., 1990; Diamanti-Kandarakis et al., 1995; Lemieux et al., 1999) or only a minor effect (Elkind-Hirsch et al., 1993; Moghetti et al., 1996; Cagnacci et al., 1999) on insulin sensitivity, and testosterone alone cannot explain insulin resistance in PCOS (Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundInfluentialRs1799817 in INSR associates with susceptibility to polycystic ovary syndrome
Daghestani, M. H. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0023 · Cited by 25
Mitochondrial function in women with polycystic ovary syndrome
Cozzolino, M., & Seli, E. U. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000619 · Cited by 24
“Polycystic ovary syndrome (PCOS) is the most prevalent benign gynecological disorder; it affects approximately 5% of women of childbearing age and causes infertility [1,2].”
BackgroundGuo, X., Puttabyatappa, M., Domino, S. E., & Padmanabhan, V. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110913 · Cited by 24
Gonadal hormones and stroke risk: PCOS as a case study
Stewart, C. E., & Sohrabji, F. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100853 · Cited by 24
Regidor, P., de la Rosa, X., Müller, A., Mayr, M., Santos, F. G., Banzo, R. G., & Rizo, J. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020456 · Cited by 24
“Excess insulin may lead to enhanced androgen synthesis by direct stimulation of androgen production on the one hand and by reducing the serum levels of sex hormone-binding globulin (SHBG) on the other, thereby contributing to the androgen excess characteristic for PCOS [8].”
BackgroundChristakou, C. D., Κόλλιας, Α., Piperi, C., Katsikis, I., Panidis, D., & Diamanti‐Kandarakis, E. (2014) · HORMONES · doi:10.14310/horm.2002.1553 · Cited by 24
“hyperandrogenemia as well as insulin resistance and a clustering of cardiovascular risk factors.(1) Even in the absence of detectable metabolic abnormalities, lean PCOS women have increased circulating levels of advanced glycated end products (AGEs), which are known proinflammatory and proatherogenic molecules.”
BackgroundSelf-citationGöbl, C. S., Ott, J., Bozkurt, L., Feichtinger, M., Rehmann, V., Cserjan, A., Heinisch, M., Steinbrecher, H., Kukurová, I. J., Klepochová, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160571 · Cited by 24
“In contrast the NIH criteria are more restrictive, defining PCOS by chronic anovulation and hyperandrogenism (regardless of polycystic ovarian morphology) [5], with consequently lower prevalence but more severe clinical presentation [1, 6].”
BackgroundResultInfluentialXia, Y., Wang, Y., Cui, M., & Su, D. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1050 · Cited by 23
“Research has shown that insulin has a gonadotropin-like action and modulates ovarian steroidogenesis; insulin signaling disruption in the brain can effect ovulation and body weight regulation (28).”
Background(2014) · doi:10.1007/978-1-4471-2789-5_13 · Cited by 23
Velissariou, M., Athanasiadou, C. R., Diamanti, A., Lykeridou, A., & Sarantaki, A. (2025) · Metabolism Open · doi:10.1016/j.metop.2024.100341 · Cited by 23
Shekarian, A., Mazaheri‐Tehrani, S., Shekarian, S., Pourbazargan, M., Setudeh, M., Abhari, A. P., Fakhrolmobasheri, M., & Heidarpour, M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01896-2 · Cited by 23
“4 Forest plot showing the weighted mean difference of HOMA-IR between patients with and without subclinical hypothyroidism activation, impairing downstream insulin signaling pathways [73].”
Balogh, Z., Csehely, S., Orosz, M., Bhattoa, H. P., Krasznai, Z. T., Deli, T., & Jakab, A. (2025) · Biomedicines · doi:10.3390/biomedicines13081803 · Cited by 23
“Hyperinsulinemia, a compensatory response to IR, stimulates ovarian androgen production while simultaneously reducing hepatic synthesis of sex hormone-binding globulin (SHBG), further increasing the bioavailability of free testosterone and worsening symptoms [8,9].”
Chen, X., Wan, Y., & Xie, L. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf197 · Cited by 23
Morris, S., Grover, S. R., & Sabin, M. A. (2015) · Clinical Obesity · doi:10.1111/cob.12123 · Cited by 23
“PCOS is associated with an increased risk of impaired glucose tolerance and insulin resistance independent of obesity in adult women (112,113).”
BackgroundPolycystic Ovary Syndrome Susceptibility Loci Inform Disease Etiological Heterogeneity
Zhang, Y., Movva, V. C., Williams, M. S., & Lee, M. T. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122688 · Cited by 24
“PCOS includes highly heterogeneous phenotypic manifestations characterized by a variety of reproductive and metabolic abnormalities, including ovulatory dysfunction, hyperandrogenism, hirsutism, obesity, and insulin resistance [1].”
BackgroundPalafox-Gómez, C., Ortiz, G. M., Madrazo, I., & López‐Bayghen, E. (2023) · Reproductive Toxicology · doi:10.1016/j.reprotox.2023.108420 · Cited by 23
Son, M., Moon, S. Y., Koh, M., Kang, Y. W., & Lee, J. Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061628 · Cited by 23
Wang, Z., van Faassen, M. H. J. R., Groen, H., Cantineau, A. E., van Oers, A. M., van der Veen, A., Hawley, J. M., Keevil, B. G., Kema, I. P., & Hoek, A. (2024) · Human Reproduction · doi:10.1093/humrep/deae058 · Cited by 23
“Excess body weight and visceral fat promote the development of insulin resistance and compensatory hyperinsulinemia, which stimulates the synthesis of androgens in the ovaries (Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundShaikh, N. J., Dadachanji, R., Meherji, P. K., Shah, N. S., & Mukherjee, S. (2015) · Gene · doi:10.1016/j.gene.2015.11.033 · Cited by 23
Connolly, A., Leblanc, S., & Baillargeon, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/4315413 · Cited by 23
“Importantly, these pathways appear to be enhanced in women with PCOS [55, 56], as opposed to the PI3K pathway that was shown to be insulin resistant [18, 19, 55, 57, 58].”
BackgroundAbbott, D. H., Vepraskas, S. H., Horton, T. H., Terasawa, E., & Levine, J. E. (2018) · Neuroendocrinology · doi:10.1159/000490570 · Cited by 20
Kong, F., Du, C., & Wang, Y. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.02.012 · Cited by 23
Jarrett, B. Y., Vantman, N., Mergler, R. J., Brooks, E. D., Pierson, R. A., Chizen, D. R., & Lujan, M. E. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00112 · Cited by 23
“, fasting insulin) having higher values than reported by others [3].”
ResultNegrón, A. L., & Radovick, S. (2020) · Endocrinology · doi:10.1210/endocr/bqaa146 · Cited by 23
Wang, W., Jiang, Q., Niu, Y., Ding, Q., Yang, X., Zheng, Y., Hao, J. C., & Wei, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.956406 · Cited by 23
Liang, P., Xi, L., Shi, J., Li, W., Zhao, S., Deng, Y., Wang, R., Sun, Y., Gu, B., Yuan, L., et al. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.029 · Cited by 23
Dallel, M., Sarray, S., Douma, Z., Hachani, F., Al-Ansari, A. K., Letaifa, D. B., Mahjoub, T., & Almawi, W. Y. (2018) · Gene · doi:10.1016/j.gene.2018.01.028 · Cited by 23
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528231 · Cited by 23
“This scenario worsens when abdominal adiposity or a hyperandrogenic phenotype is present [14,22].”
BackgroundInfluentialAssociation of Adiponectin and rs1501299 of the ADIPOQ Gene with Prediabetes in Jordan
Alfaqih, M. A., Al‐Μughales, F., Al-Shboul, O. A., Alqudah, M., Khader, Y. S., & Al-Jarrah, M. (2018) · Biomolecules · doi:10.3390/biom8040117 · Cited by 23
“A common feature of all of the above conditions is that they all could be affected/modulated by insulin resistance [12,25].”
BackgroundOrio, F., Muscogiuri, G., & Palomba, S. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2015.53 · Cited by 23
Day, F. R., Karaderi, T., Jones, M. R., Meun, C., He, C., Drong, A. W., Kraft, P. L., Lin, N., Huang, H., Broer, L., et al. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008517 · Cited by 23
Self-citationThe role of immunity in insulin resistance in patients with polycystic ovary syndrome
Zhang, Q., Yang, Z., Ou, X., Zhang, M., Qin, X., & Wu, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1464561 · Cited by 22
Özbek, L., Shah, E., Al-Shiab, R., İnal, A., Güldan, M., Afşar, B., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70699 · Cited by 22
Richards, C. T., Meah, V. L., James, P. E., Rees, A., & Lord, R. N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.715881 · Cited by 23
“Anthropometric Profile Overweight and obesity are prevalent in more than 50% of individuals with PCOS and have the potential to exacerbate symptoms of the condition (Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundPerović, M., Wugalter, K. A., & Einstein, G. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101038 · Cited by 22
Wang, R., Zhao, Y., Fang, X., Miao, C., Ren, N., Chen, Y., Cheng, W., & Zhang, Q. (2023) · Nutrition · doi:10.1016/j.nut.2023.112127 · Cited by 22
Zhang, M., Liu, C., Yuan, X.-Q., Cui, F., Yu, M., Yao, W., Qin, D.-Y., Deng, Y.-L., Chen, P., Zeng, J.-Y., et al. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2023.104233 · Cited by 22
Zhang, Z., Shi, C., & Wang, Z. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1279469 · Cited by 22
Alsaadi, H., & Vugt, D. A. V. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0048 · Cited by 22
Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism
Zhao, S., Xu, H., Cui, Y., Wang, W., Qin, Y., Li, Y., Chan, W., Sun, Y. W., & Chen, Z. (2016) · Endocrine · doi:10.1007/s12020-016-0949-y · Cited by 22
Amer, S. A. K. S., Alzanati, N. G., Warren, A., Tarbox, R., & Khan, R. N. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0674 · Cited by 22
Adipose Insulin Resistance and Circulating Betatrophin Levels in Women with PCOS
He, Y., Hu, W., Yang, G., Guo, H., Liu, H., & Li, L. (2020) · BioMed Research International · doi:10.1155/2020/1253164 · Cited by 22
“In addition to IR in the liver and muscle tissues, IR in fat tissue is also an important feature in PCOS subjects, especially in obese women [29, 30].”
BackgroundLow Vitamin D Level in Saudi Women With Polycystic Ovary Syndrome
Bindayel, I. A. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.611351 · Cited by 22
Zhu, Q., Yao, Y., Xu, L., Wu, H., Wang, W., He, Y., Wang, Y., Lu, Y., Qi, J., Ding, Y., et al. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-021-00873-3 · Cited by 22
“The key characteristics of PCOS include anovulation, hyperandrogenism, polycystic ovarian morphology and insulin resistance (IR) [2, 3].”
BackgroundBulsara, J., Soni, A., Patil, P., Halpati, K., Desai, S., & Acharya, S. R. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09932-6 · Cited by 22
“Polycystic ovarian syndrome is a metabolic condition that is attributed to various modalities including diabetes mellitus (type 2), initiated by high glucose level which gradually leads to insulin resistance [40, 41].”
BackgroundType 2 diabetes in children and adolescents: distinct characteristics and evidence-based management
Karavanaki, K., Paschou, S. Α., Tentolouris, N., Karachaliou, F., & Soldatou, A. (2022) · Endocrine · doi:10.1007/s12020-022-03172-y · Cited by 22
Clinical implications of menstrual cycle length in oligomenorrhoeic young women
Oh, J. Y., Sung, Y., & Lee, H. J. (2013) · Clinical Endocrinology · doi:10.1111/cen.12243 · Cited by 22
Fruzzetti, F., Ghiadoni, L., Virdis, A., Negri, F. D., Perini, D., Bucci, F., Giannarelli, C., Gadducci, A., & Taddei, S. (2016) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2016.03.004 · Cited by 22
Polycystic ovary syndrome in adolescent girls
Baldauff, N. H., & Witchel, S. F. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000309 · Cited by 22
Can resistance training improve the symptoms of polycystic ovary syndrome?
Pericleous, P., & Stephanides, S. (2018) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2018-000372 · Cited by 22
“Postbinding defect in receptor signalling that disturbs the metabolic pathways in classic insulin target tissues, constitutive activation of serine kinases in the MAPK-ERK pathway and androgen levels contribute to this insulin resistance.(17) In layman’s terms, genetics and lifestyle affect hormonal changes, insulin r…”
BackgroundRichards, J. S., Liu, Z., & Shimada, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00022-3 · Cited by 22
Kulkarni, S. D., Patil, A. N., Gudi, A., Homburg, R., & Conway, G. S. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.05.021 · Cited by 21
Palomba, S., Seminara, G., Costanzi, F., Caserta, D., & Aversa, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122859 · Cited by 21
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.